{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:05:50Z","timestamp":1791176750186,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T00:00:00Z","timestamp":1172016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>CXC chemokine receptor 4 (CXCR4) expression in acute myeloid leukemia (AML) is reported to correlate with <jats:italic>FLT3<\/jats:italic> gene mutation and poorer prognosis. The prognostic significance of CXCR4 expression in patients with AML that have a normal karyotype and no evidence of <jats:italic>FLT3<\/jats:italic> gene mutations was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>The prognostic significance of CXCR4 expression in 122 AML patients with normal karyotype and no evidence of <jats:italic>FLT3<\/jats:italic> gene mutation treated at our institution between 1997 and 2003 was analyzed. All patients received intensive chemotherapy according to institutional protocols; 84% received cytarabine\u2010containing regimens. Bone marrow biopsy or clot specimens obtained before treatment were immunostained for CXCR4.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>There were 70 men and 52 women with a median age of 62 years (range, 22\u201382 years). Median follow\u2010up was 18 months (range, &lt;1\u201397 months). Seventy\u2010six patients achieved complete remission (CR); 39 had recurrence. Sixty\u2010six patients died, including 9 with no evidence of disease. CXCR4 was positive in 70 and negative in 52 patients, with CR rates of 58% and 71%, respectively (<jats:italic>P<\/jats:italic> = .09). Multivariate analysis demonstrated that CXCR4 expression, presence of multilineage dysplasia, and high creatinine level predicted poorer overall (OS) and event\u2010free (EFS) survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The results suggest that CXCR4 expression is associated with poor prognosis in AML patients with an unmutated <jats:italic>FLT3<\/jats:italic> gene. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22510","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T17:53:04Z","timestamp":1172080384000},"page":"1152-1156","source":"Crossref","is-referenced-by-count":139,"title":["Overexpression of CXCR4 predicts adverse overall and event\u2010free survival in patients with unmutated <i>FLT3<\/i> acute myeloid leukemia with normal karyotype"],"prefix":"10.1002","volume":"109","author":[{"given":"Sergej","family":"Konoplev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios Z.","family":"Rassidakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula I.","family":"Liakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,2,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.3.1101"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-005-3222-y"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2004.12.007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0802"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03164.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0566"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024844"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1309\/JQMR-323G-71Y9-M7MB"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05666.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1194"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4049\/jimmunol.160.2.877","article-title":"Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV\u20101 infectivity","volume":"160","author":"Hesselgesser J","year":"1998","journal-title":"J Immunol."},{"key":"e_1_2_6_13_2","first-page":"246","article-title":"Identification of a group of AML\/MDS patients with a relatively favorable prognosis who have chromosome 5 and\/or 7 abnormalities","volume":"85","author":"Estey EH","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1440"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.72"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:20:43Z","timestamp":1760300443000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,21]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3,15]]}},"alternative-id":["10.1002\/cncr.22510"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22510","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,21]]}}}